Literature DB >> 5924082

The pathogenicity of the Ehrlich ascites tumour.

K D Mayer.   

Abstract

Entities:  

Mesh：

Year:  1966        PMID： 5924082      PMCID： PMC2093716     

Source DB:  PubMed          Journal:  Br J Exp Pathol        ISSN： 0007-1021


× No keyword cloud information.
  4 in total

1.  [Contribution to the study of Ehrilich's experimental mouse cancer].

Authors:  M PELLET; J BROSSON
Journal:  J Med Lyon       Date:  1961-05-05

2.  Production in mice of large volumes of ascites fluid containing antibodies.

Authors:  J MUNOZ
Journal:  Proc Soc Exp Biol Med       Date:  1957 Aug-Sep

3.  Studies of antibodies in ascitic fluid of individual mice.

Authors:  R LIEBERMAN; N MANTEL; W HUMPHREY; J G BLAKELY
Journal:  Proc Soc Exp Biol Med       Date:  1962 Aug-Sep

4.  The antigenic composition of mouse ascites tumour cells using in vitro and gel-diffusion techniques.

Authors:  G C EASTY; E J AMBROSE
Journal:  Br J Cancer       Date:  1957-06       Impact factor: 7.640
  4 in total
  4 in total

1.  [Immunologically induced inhibition and enhancement of tumor growth (EAT): significance of different antigenic preparations (author's transl)].

Authors:  K Schweizer; G Gillissen; W Lutzeyer
Journal:  Med Microbiol Immunol       Date:  1974-03-22       Impact factor: 3.402

2.  Serum ceruloplasmin in mice with Ehrlich ascites carcinoma.

Authors:  L A Abreu; R R Abreu
Journal:  Experientia       Date:  1971-01-15

3.  [Growth of solid Ehrlich ascites tumors in mice following BCG immunization].

Authors:  G Gillissen; G Nehring
Journal:  Beitr Klin Erforsch Tuberk Lungenkr       Date:  1969

4.  The Ehrlich tumor induces pain-like behavior in mice: a novel model of cancer pain for pathophysiological studies and pharmacological screening.

Authors:  Cassia Calixto-Campos; Ana C Zarpelon; Mab Corrêa; Renato D R Cardoso; Felipe A Pinho-Ribeiro; Rubens Cecchini; Estefania G Moreira; Jefferson Crespigio; Catia C F Bernardy; Rubia Casagrande; Waldiceu A Verri
Journal:  Biomed Res Int       Date:  2013-08-29       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.